Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Biocryst Pharmaceuticals Inc (BCRX) AI Forecast

Our AI detected a significant signal for Biocryst Pharmaceuticals Inc. Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$BCRX Bullish Signal Full forecast available
Sign Up Free

Biocryst Pharmaceuticals Inc (BCRX) Stock Forecast 2025

Biocryst Pharmaceuticals Inc (BCRX) AI Stock Price Forecast & Investment Analysis

Biocryst Pharmaceuticals Inc Stock Price Chart and Technical Analysis

Loading chart...

Biocryst Pharmaceuticals Inc (BCRX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Biocryst Pharmaceuticals Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 2:58 p.m. (UTC)

Biocryst Pharmaceuticals Inc Investment Summary

When evaluating whether Biocryst Pharmaceuticals Inc (BCRX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Biocryst Pharmaceuticals Inc (BCRX) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $2 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Biocryst Pharmaceuticals Inc's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Biocryst Pharmaceuticals Inc along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Biocryst Pharmaceuticals Inc is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Biocryst Pharmaceuticals Inc

Sign Up Free
Corporate Identity

Biocryst Pharmaceuticals Inc (Stock Symbol: BCRX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Biocryst Pharmaceuticals Inc's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Biocryst Pharmaceuticals Inc...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Biocryst Pharmaceuticals Inc...

Unlock Full Company Profile

Get complete details about Biocryst Pharmaceuticals Inc

Sign Up Free
Revenue & Growth Analysis

Biocryst Pharmaceuticals Inc generates annual revenues of $885 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Biocryst Pharmaceuticals Inc...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Biocryst Pharmaceuticals Inc...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Biocryst Pharmaceuticals Inc...

Unlock Financial Analysis

Get complete financial metrics for Biocryst Pharmaceuticals Inc

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Biocryst Pharmaceuticals Inc's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Biocryst Pharmaceuticals Inc strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Biocryst Pharmaceuticals Inc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company shows positive operational efficiency through free cash flow generation of $310 million annually . Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.

Asset Utilization Efficiency

Asset turnover ratio of 1.90x indicates exceptional efficiency in utilizing company assets to generate revenue. High asset turnover is characteristic of retail, distribution, or service businesses that operate with relatively lean asset bases. This efficiency translates to higher returns on invested capital when combined with reasonable margins.

Financial Strength & Leverage

Current ratio of 1.91 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Biocryst Pharmaceuticals Inc (BCRX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Biocryst Pharmaceuticals Inc stock analysis.

Deep dive into Biocryst Pharmaceuticals Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Biocryst Pharmaceuticals Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Biocryst Pharmaceuticals Inc:

Market Cap $2.38B
Revenue/Share $3.49
FCF/Share $1.22
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Biocryst Pharmaceuticals Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Biocryst Pharmaceuticals Inc: An ROE of 21.2% demonstrates excellent shareholder value creation.

ROE 21.2%
ROA -25.2%
ROIC -38.2%
Operating Margin -280.7%
Net Margin -319.5%
EBT Margin -280.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Biocryst Pharmaceuticals Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Biocryst Pharmaceuticals Inc: A current ratio of 1.91 shows adequate liquidity.

Current Ratio 1.91x
Quick Ratio 1.88x
D/E Ratio -1.84x
Financial Leverage -0.84x
Interest Coverage -115.3x
Working Capital $178M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Biocryst Pharmaceuticals Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Biocryst Pharmaceuticals Inc: Free cash flow of $310M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow -$71M
Free Cash Flow $310M
Capital Spending $382M
FCF/Sales 35.0%
CapEx/Sales 43.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Biocryst Pharmaceuticals Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Biocryst Pharmaceuticals Inc: An asset turnover of 1.90x demonstrates efficient asset utilization.

Asset Turnover 1.90x
Receivables Turnover 8.1x
Fixed Assets Turnover 94.6x
Days Sales Outstanding 45 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Biocryst Pharmaceuticals Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Biocryst Pharmaceuticals Inc: With annual revenue of $885M, Biocryst Pharmaceuticals Inc demonstrates solid business size.

Income Statement
Total Revenue $885M
Operating Income -$102M
Net Income -$117M
R&D Expense $108M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 374%
Cash & Short-term Investments 172%
Total Liabilities 1019%
Short-term Debt 184%
Accounts Receivable 109%
Inventory 6%
Dividend & Shareholder Information
Shares Outstanding 254M
Growth Metrics (YoY)
Net Income Growth -319.5%

Latest Biocryst Pharmaceuticals Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Biocryst Pharmaceuticals Inc (BCRX) stock price and investment outlook.

📰 Loading...

Biocryst Pharmaceuticals Inc Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Biocryst Pharmaceuticals Inc against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $27M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $18M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $488M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $186M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Biocryst Pharmaceuticals Inc Stock Forecast

How accurate are Biocryst Pharmaceuticals Inc stock predictions?

Our AI model shows a -14% Spearman correlation coefficient for BCRX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Biocryst Pharmaceuticals Inc stock price forecasts?

Our analysis considers Biocryst Pharmaceuticals Inc's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Biocryst Pharmaceuticals Inc a good investment in 2025?

Based on our AI analysis, Biocryst Pharmaceuticals Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Biocryst Pharmaceuticals Inc forecasts updated?

Biocryst Pharmaceuticals Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Biocryst Pharmaceuticals Inc?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...